Lynnezy Laurencin, MD
Psychiatry · Tustin, CANPI 1619354297
Payments from drug & device makers
Across 751 payments — averaging $25.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- AbbVie$3K
- Johnson & Johnson$2K
- Neurocrine Biosciences, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $5K from 24 others
What the payments were for
- Food & beverage$18,95099%
- Education$2481%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 129 | $3,142 |
| AbbVie(2 entities) | 95 | $2,670 |
| Johnson & Johnson | 92 | $2,399 |
| Neurocrine Biosciences, Inc. | 72 | $2,368 |
| Otsuka America Pharmaceutical, Inc. | 78 | $2,139 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 47 | $1,082 |
| Acadia Pharmaceuticals Inc | 45 | $1,074 |
| Axsome Therapeutics, Inc. | 25 | $970 |
| Vanda Pharmaceuticals Inc. | 24 | $538 |
| Lundbeck LLC | 26 | $436 |
| Alkermes, Inc. | 14 | $421 |
| E.r. Squibb & Sons, L.L.C. | 7 | $217 |
| Indivior Inc. | 11 | $210 |
| Livanova USA, Inc. | 4 | $204 |
| Sunovion Pharmaceuticals Inc. | 22 | $198 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $158 |
| Merck | 9 | $147 |
| Noven Therapeutics, LLC | 6 | $132 |
| Idorsia Pharmaceuticals US Inc | 7 | $125 |
| Bausch Health US, LLC | 5 | $89 |
| Avanir Pharmaceuticals, Inc. | 4 | $78 |
| Eisai Inc. | 4 | $72 |
| Harmony Biosciences LLC | 2 | $72 |
| Corium, LLC | 3 | $59 |
| Ironshore Pharmaceuticals Inc. | 3 | $54 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Lilly USA, LLC | 1 | $35 |
| Adlon Therapeutics L.p. | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Medline Industries LP | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$736
- VRAYLAR$727
- ABILIFY MAINTENA$490
- Auvelity$484
- LYBALVI$482
- AUSTEDO$425
- REXULTI$355
- INVEGA SUSTENNA$261
- CAPLYTA$259
- ABILIFY ASIMTUFII$125
- UZEDY$125
- Austedo XR$122
- VNS Therapy Symmetry Model 8103 Generator$118
- INVEGA TRINZA$111
How this compares
$19,198 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 71 | $578,315 |
| VraylarCariprazine Hcl | 282 | $426,664 |
| UzedyRisperidone | 103 | $354,633 |
| IngrezzaValbenazine Tosylate | 35 | $277,280 |
| AristadaAripiprazole Lauroxil | 47 | $148,879 |
| AustedoDeutetrabenazine | 11 | $140,828 |
| Invega SustennaPaliperidone Palmitate | 44 | $136,930 |
| RexultiBrexpiprazole | 77 | $124,705 |
| TrintellixVortioxetine Hydrobromide | 173 | $100,034 |
| Abilify MaintenaAripiprazole | 34 | $88,817 |
| NuedextaDextromethorphan Hbr/Quinidine | 59 | $88,688 |
| Abilify AsimtufiiAripiprazole | 13 | $65,116 |
| BelsomraSuvorexant | 130 | $58,377 |
| LybalviOlanzapine/Samidorphan Malate | 28 | $42,991 |
| CaplytaLumateperone Tosylate | 22 | $37,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy, Austedo | $3,142 | $1,073,776185 claims |
| AbbVieVraylar, Ubrelvy | $2,670 | $454,914298 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena, Abilify Asimtufii | $2,139 | $278,638124 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,368 | $277,28035 claims |
| Johnson & JohnsonInvega Sustenna, Spravato, Risperdal Consta | $2,399 | $194,07471 claims |
| Alkermes, Inc.Aristada, Lybalvi | $421 | $191,87075 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $158 | $100,034173 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $78 | $88,68859 claims |
| MerckBelsomra | $147 | $58,377130 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,082 | $37,52022 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $538 | $35,06317 claims |
| Axsome Therapeutics, Inc.Auvelity | $970 | $25,27322 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Tustin
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
- Donald AndersonBanning$10.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.